Researchers identify source of a brain cancer’s deadly transformation
Broad Institute
NOVEMBER 21, 2024
Their results underscore the importance of early detection and treatment, such as with vorasidenib , which targets IDH and was recently approved by the FDA for low-grade gliomas. In IDH-driven gliomas, the mutated IDH enzyme fosters the addition of methyl groups to the cells’ DNA.
Let's personalize your content